Targeting TIM-3 and LAG-3 Receptors in Small Cell Lung Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for small cell lung cancer, particularly those targeting PD-1 or CTLA-4, are insufficient due to limited understanding of the interaction between small cell lung cancer cells and the immune system, leading to rapid drug resistance and poor patient outcomes, with a need for more specific immunotherapy approaches.
Innovation Solution
Development of inhibitors targeting T cell co-inhibitory receptors TIM-3 and LAG-3, specifically induced by CD44+ CD90+ cancer stem cells, including small molecule inhibitors, antagonists, gene silencing compositions, and bispecific antibodies, to enhance the interaction between SCLC cells and T cells, offering a more precise targeting mechanism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-PD-1, anti-PD-L1 and anti-CTLA-4 treatments are used for small cell lung cancer, then immunotherapy approach is applied, but treatment effectiveness is insufficient and rapid drug resistance develops
Solution Approach 1:
The patent changes the target parameter from PD-1/CTLA-4 to TIM-3 and LAG-3 receptors, which are differently expressed in small cell lung cancer. This parameter change enables more effective targeting of cancer stem cells and their immune regulatory mechanisms, overcoming the limitations of conventional immunotherapy targets in SCLC
Solution Approach 2:
The patent introduces TIM-3 and LAG-3 as intermediary molecules that mediate the interaction between cancer stem cells and the immune system. These intermediaries represent critical control points for immune evasion in SCLC, providing new therapeutic targets that bridge the gap between tumor cells and immune responses
2Productivity
If platinum-based chemotherapeutics are used for small cell lung cancer, then initial response is good, but therapy resistance develops quickly
Solution Approach 1:
The patent segments the cancer cell population into cancer stem cells (CD44+ CD90+) and differentiated cells, targeting specifically the stem cell subset that drives therapy resistance. By focusing on this segmented subpopulation, the treatment can address the root cause of rapid resistance development rather than treating all cells uniformly
Solution Approach 2:
The patent replaces the mechanical/chemical action of platinum-based chemotherapeutics with an immunological mechanism targeting TIM-3 and LAG-3 receptors on cancer stem cells. This substitution enables a more durable response by attacking the immune regulatory mechanisms that protect cancer stem cells from conventional chemotherapy
3Adaptability or versatility
If conventional immunotherapy targets (PD-1, CTLA-4) are used, then general cancer treatment approach is applied, but specific targeting for small cell lung cancer is insufficient
Solution Approach 1:
The patent applies local quality by identifying and targeting TIM-3 and LAG-3 receptors that are specifically and highly expressed on cancer stem cells in small cell lung cancer, rather than using broadly expressed targets like PD-1. This localized targeting approach maximizes specificity for the SCLC stem cell population while maintaining immunotherapy mechanisms
Data Source
AI summary
Expression of TIM-3 and LAG-3 co-inhibitory molecules on T cells induced by CD44+ CD90+ cancer stem cells more than other co-inhibitor molecules/receptors in small cell lung cancer (SCLC). Furthermore, the uses related to targeting TIM-3 and LAG-3 co-inhibitory molecules whose expression in T cells is increased in small cell lung cancer is provided.